Arexvy

On May 3, 2023 the US Food and Drug Administration (FDA) has approved the world’s first respiratory syncytial virus (RSV) vaccine called Arexvy.

About Arexvy vaccine

• Purpose: World’s first respiratory syncytial virus (RSV) vaccine for older adults (age 60 or more).
  Approved by: US FDA
• Developed by: GSK plc, UK

What is Respiratory Syncytial Virus (RSV)?

• Respiratory syncytial (sin-SISH-uhl) virus, or RSV, is a common respiratory virus that usually causes mild, cold-like symptoms.
• Most people recover in a week or two, but RSV can be serious, especially for infants and older adults.